{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T21:58:45Z","timestamp":1764194325675},"reference-count":22,"publisher":"Spandidos Publications","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Exp Ther Med"],"DOI":"10.3892\/etm.2019.7196","type":"journal-article","created":{"date-parts":[[2019,1,23]],"date-time":"2019-01-23T11:26:40Z","timestamp":1548242800000},"source":"Crossref","is-referenced-by-count":4,"title":["Therapeutic effects of rituximab combined with cyclophosphamide on refractory idiopathic thrombocytopenic purpura"],"prefix":"10.3892","author":[{"given":"Jiuhe","family":"Wang","sequence":"first","affiliation":[{"name":"Department of Hematology, Qingdao Hiser Medical Group, Qingdao, Shandong 266000, P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bin","family":"Wang","sequence":"additional","affiliation":[{"name":"Ward Pharmacy, Qingdao Municipal Hospital, Qingdao, Shandong 266000, P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhonghui","family":"Sun","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, The Eighth People's Hospital of Qingdao, Qingdao, Shandong 266000, P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kezeng","family":"Xue","sequence":"additional","affiliation":[{"name":"Ward Pharmacy, Qingdao Municipal Hospital, Qingdao, Shandong 266000, P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2249","published-online":{"date-parts":[[2019,1,23]]},"reference":[{"key":"key20200713120219_b1-etm-0-0-7196","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/j.jpeds.2017.08.036","article-title":"Treatment of children with persistent and chronic idiopathic thrombocytopenic purpura: 4 infusions of rituximab and three 4-day cycles of dexamethasone","volume":"191","author":"Oved","year":"2017","journal-title":"J Pediatr"},{"key":"key20200713120219_b2-etm-0-0-7196","first-page":"197","article-title":"High-dose dexamethasone therapy as the initial treatment for idiopathic thrombocytopenic purpura: Protocol for a multicenter, open-label, single arm trial","volume":"72","author":"Takase","year":"2018","journal-title":"Acta Med Okayama"},{"key":"key20200713120219_b3-etm-0-0-7196","first-page":"1045","article-title":"Advances of research on abnormality of cell immunity in idiopathic thrombocytopenic purpura: Review","volume":"14","author":"Zhao","year":"2006","journal-title":"Zhongguo Shi Yan Xue Ye Xue Za Zhi"},{"key":"key20200713120219_b4-etm-0-0-7196","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1111\/jth.13940","article-title":"The association between idiopathic thrombocytopenic purpura and cardiovascular disease: A retrospective cohort study","volume":"16","author":"Chandan","year":"2018","journal-title":"J Thromb Haemost"},{"key":"key20200713120219_b5-etm-0-0-7196","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.2217\/imt-2017-0071","article-title":"Gammaplex\u00ae 5 and 10% in the treatment of primary immunodeficiency and chronic immune thrombocytopenic purpura","volume":"9","author":"Wasserman","year":"2017","journal-title":"Immunotherapy"},{"key":"key20200713120219_b6-etm-0-0-7196","doi-asserted-by":"publisher","first-page":"5","DOI":"10.2217\/imt-2017-0141","article-title":"Spleen tyrosine kinase inhibition: A new promising approach to chronic and refractory immune thrombocytopenia","volume":"10","author":"Niscola","year":"2018","journal-title":"Immunotherapy"},{"key":"key20200713120219_b7-etm-0-0-7196","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.15177","article-title":"Rituximab-induced acute and delayed serum sickness in thrombotic thrombocytopenic purpura: The role of anti-rituximab antibodies","author":"Vendramin","year":"2018","journal-title":"Br J Haematol"},{"issue":"pii","key":"key20200713120219_b8-etm-0-0-7196","article-title":"Treatment of immune thrombocytopenic purpura associated with cytomegalovirus infection in a child with pre-B cell acute lymphoblastic leukaemia after central nervous system relapse","volume":"2017","author":"Martinez","year":"2017","journal-title":"BMJ Case Rep"},{"key":"key20200713120219_b9-etm-0-0-7196","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1182\/bloodadvances.2017005124","article-title":"Thrombotic thrombocytopenic purpura: Diagnostic criteria, clinical features, and long-term outcomes from 1995 through 2015","volume":"1","author":"Page","year":"2017","journal-title":"Blood Adv"},{"key":"key20200713120219_b10-etm-0-0-7196","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1111\/j.1365-2141.2010.08140.x","article-title":"Development of romiplostim for the treatment of patients with chronic immune thrombocytopenia: From bench to bedside","volume":"150","author":"Molineux","year":"2010","journal-title":"Br J Haematol"},{"key":"key20200713120219_b11-etm-0-0-7196","doi-asserted-by":"publisher","first-page":"161","DOI":"10.4103\/IJPM.IJPM_225_17","article-title":"Hyperheptaploidy in idiopathic thrombocytopenic purpura","volume":"61","author":"Chowdhry","year":"2018","journal-title":"Indian J Pathol Microbiol"},{"key":"key20200713120219_b12-etm-0-0-7196","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1007\/BF02983791","article-title":"Serum immunoglobulin levels at onset: Association with the prognosis of childhood idiopathic thrombocytopenic purpura","volume":"77","author":"Kubota","year":"2003","journal-title":"Int J Hematol"},{"key":"key20200713120219_b13-etm-0-0-7196","doi-asserted-by":"crossref","first-page":"e572","DOI":"10.1097\/MJT.0000000000000654","article-title":"Intravenous immunoglobulin-induced profound bradycardia in a patient with idiopathic thrombocytopenic purpura","volume":"25","author":"Raheja","year":"2018","journal-title":"Am J Ther"},{"key":"key20200713120219_b14-etm-0-0-7196","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1097\/MBC.0000000000000646","article-title":"Association between gene polymorphisms and clinical features in idiopathic thrombocytopenic purpura patients","volume":"28","author":"Rezaeeyan","year":"2017","journal-title":"Blood Coagul Fibrinolysis"},{"key":"key20200713120219_b15-etm-0-0-7196","doi-asserted-by":"publisher","first-page":"1448","DOI":"10.1111\/jth.13716","article-title":"Caplacizumab reduces the frequency of major thromboembolic events, exacerbations and death in patients with acquired thrombotic thrombocytopenic purpura","volume":"15","author":"Peyvandi","year":"2017","journal-title":"J Thromb Haemost"},{"key":"key20200713120219_b16-etm-0-0-7196","doi-asserted-by":"publisher","first-page":"e2012056","DOI":"10.4084\/mjhid.2012.056","article-title":"Platelet count response to Helicobacter pylori eradication in Iranian patients with idiopathic thrombocytopenic purpura","volume":"4","author":"Payandeh","year":"2012","journal-title":"Mediterr J Hematol Infect Dis"},{"key":"key20200713120219_b17-etm-0-0-7196","doi-asserted-by":"publisher","first-page":"2096186","DOI":"10.1155\/2018\/2096186","article-title":"Hypogammaglobulinemia observed one year after rituximab treatment for idiopathic thrombocytopenic purpura","volume":"2018","author":"Shoukat","year":"2018","journal-title":"Case Rep Med"},{"key":"key20200713120219_b18-etm-0-0-7196","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1002\/jca.21514","article-title":"Human immunodeficiency virus associated thrombotic thrombocytopenic purpura, a clinical conundrum","volume":"32","author":"Warner","year":"2017","journal-title":"J Clin Apher"},{"key":"key20200713120219_b19-etm-0-0-7196","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1111\/ejh.12831","article-title":"Familial acquired thrombotic thrombocytopenic purpura in siblings - no immunogenetic link with associated human leucocyte antigens","volume":"98","author":"G\u00f6del","year":"2017","journal-title":"Eur J Haematol"},{"key":"key20200713120219_b20-etm-0-0-7196","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1186\/s12882-018-0868-7","article-title":"Immune thrombocytopenic purpura presenting in a patient after renal transplant for diabetic nephropathy","volume":"19","author":"Rashid","year":"2018","journal-title":"BMC Nephrol"},{"key":"key20200713120219_b21-etm-0-0-7196","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1001\/archsurg.139.1.61","article-title":"Predictive factors for successful laparoscopic splenectomy in patients with immune thrombocytopenic purpura","volume":"139","author":"Duperier","year":"2004","journal-title":"Arch Surg"},{"key":"key20200713120219_b22-etm-0-0-7196","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1007\/s12185-017-2325-y","article-title":"Splenectomy vs. rituximab as a second-line therapy in immune thrombocytopenic purpura: A single center experience","volume":"107","author":"Al Askar","year":"2018","journal-title":"Int J Hematol"}],"container-title":["Experimental and Therapeutic Medicine"],"original-title":[],"deposited":{"date-parts":[[2024,7,14]],"date-time":"2024-07-14T07:59:52Z","timestamp":1720943992000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.spandidos-publications.com\/10.3892\/etm.2019.7196"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1,23]]},"references-count":22,"URL":"https:\/\/doi.org\/10.3892\/etm.2019.7196","relation":{},"ISSN":["1792-0981","1792-1015"],"issn-type":[{"value":"1792-0981","type":"print"},{"value":"1792-1015","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,1,23]]}}}